MDACC Study No:2006-0079 ( NCT No: NCT00416793)
Title:A Phase II Study of Bortezomib in Combination with Carboplatin In Patients With Metastatic Pancreatic Cancer
Principal Investigator:Gauri Varadhachary
Treatment Agent:Bortezomib; Carboplatin
Study Status:Terminated
Study Description:The goal of this clinical research study is to find out how effective the
combination of bortezomib and carboplatin is against advanced cancer of the
pancreas. The safety of this treatment will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Pancreas
Phase of Study:Phase II
Treatment Agents:Bortezomib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:NA
Supported By:N/A
Return Visit:On Days 1, 4, 8, and 11 of each 21-day cycle. Cycles will be repeated every 3
Home Care:NA

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gauri Varadhachary
Dept:Gastrointestinal Medical Oncology
For Clinical Trial Enrollment:713-792-2828
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults